A study to assess the safety, tolerability and pharmacokinetics of AZD4041 in Healthy Volunteers

Study identifier:D7460C00001

ClinicalTrials.gov identifier:NCT04076540

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A phase I randomized, double-blind placebo-controlled study to assess the safety, tolerability, and pharmacokinetics of AZD4041 following single ascending dose administration to Healthy Volunteers

Medical condition

Smoking cessation

Phase

Phase 1

Healthy volunteers

Yes

Study drug

AZD4041, Placebo

Sex

All

Actual Enrollment

48

Study type

Interventional

Age

18 Years - 65 Years

Date

Study Start Date: 03 Oct 2019
Primary Completion Date: 02 Jan 2022
Study Completion Date: 02 Jan 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Jun 2024 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

National Institutes of Health (NIH), Eolas Therapeutics INC.

Inclusion and exclusion criteria